COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
Silverback Therapeutics develops ImmunoTAC antibody‑drug conjugates that systemically deliver immune‑modulating payloads which activate locally at disease sites; lead candidate SBT6050 is an anti‑HER2 TLR8‑agonist in clinical trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
